US 7947725

I'll search for current information on this specific patent number, including any CAFC activity.

Let me do one more targeted check for any 2026 appellate activity and the patent's current legal status.

Let me verify the appellate outcome for this patent family before finalizing.

US 7,947,725 B2 — Analyst Summary

Scope & method note: I have no direct API access to USPTO PatentCenter/PAIR or the CAFC docket system in this session. The following is drawn from the authoritative full patent text supplied in your message (Google Patents mirror of USPTO data) plus targeted live web searches. Where a live source conflicts with that text, I flag it. No 2026 Federal Circuit docket or filing involving patent 7,947,725 surfaced in searching; the absence of a hit is not proof of absence, so treat that as "nothing found," not "confirmed none."

1. Bibliographic data

Inventor nuance: the two sets of inventors reflect two assignments of interest recorded Feb. 16, 2011 — the Helsinn-side inventors (Calderari, Bonadeo, Cannella, E. Braglia, R. Braglia) and the Roche Palo Alto–side inventors (Miksztal, Malefyt, Lee). Roche Palo Alto's interest was later assigned to Helsinn (recorded May 11, 2016).

Term/expiry — flagging a conflict. The Orange Book (via FDA ANDA approval letters and the GreyB drug-patent database) lists the '725 patent as expiring July 30, 2024 with pediatric exclusivity added (base term to ~Jan. 30, 2024). Google Patents instead shows "2025-07-21 Anticipated expiration" and a 12th-year maintenance fee paid Oct. 20, 2022. I cannot reconcile these from available sources; the Orange Book date is the one that governed generic approval timing. Either way, the patent is expired as of today (April 26, 2026).

2. Abstract (verbatim)

"The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments."

3. Plain-language overview of the independent claims

The patent has only two claims, and both are independent (there are no dependent claims). Both are directed to a sterile injectable aqueous solution of palonosetron hydrochloride, and both recite mannitol as a tonicifier and EDTA as a chelating/stabilizing agent at an acidic pH.

Claim 1 — A pharmaceutically stable solution for reducing emesis, or reducing the likelihood of emesis, containing four elements:

• (a) palonosetron hydrochloride at 0.03–0.2 mg/mL, measured as free base;
• (b) a sterile injectable aqueous carrier buffered to pH 4–6;
• (c) mannitol in a tonicifying-effective amount (i.e., enough to make the solution roughly isotonic, not as a sweetener); and
• (d) EDTA at 0.005–1.0 mg/mL.

Claim 2 — Same general solution, but with narrower/point values:

• (a) palonosetron hydrochloride at exactly 0.05 mg/mL (free base basis) in a sterile injectable aqueous carrier at pH 4.5–5.5;
• (b) EDTA at 0.005–1.0 mg/mL; and
• (c) mannitol in an amount sufficient to tonicify, specifically 10–80 mg/mL.

Practical read: these are formulation (composition) claims for the commercial ALOXI®-type IV solution — a low-concentration, pH-5-ish, mannitol-tonicified, EDTA-stabilized palonosetron injection. Notably, neither claim expressly recites a citrate buffer, even though citrate is central to the specification's Examples 4–5 and to the description; the buffer limitation is captured only indirectly via the recited pH range. Claim 1's palonosetron range (0.03–0.2 mg/mL) is broader than claim 2's single 0.05 mg/mL value.

4. Legal status, litigation, and appellate history

• Expired. Google Patents shows grant May 24, 2011, 4th/8th/12th-year maintenance fees paid (2014, 2018, 2022), and "Anticipated expiration" listed as 2025-07-21. A certificate of correction (May 14, 2013) and a reissue application (filed Aug. 13, 2013, effective date stated as 2013-05-22) appear in the legal events — I could not confirm the disposition of that reissue from available sources.
• Litigation: numerous ANDA suits in D.N.J. and D. Del. (Dr. Reddy's, Teva, Sandoz, Accord, Exela, and others). The '725 patent was asserted in the Helsinn v. Teva line of cases; the PTAB petition materials state that plaintiffs asserted claim 2 of the '725 patent (along with claims 2 & 9 of the '724 patent and claims 2, 5 & 6 of the '424 patent).
• Appellate outcome — important: In Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017), the Federal Circuit reversed the district court's validity holding and expressly held: "the asserted claims, claims 2 and 9 of the '724 patent, claim 2 of the '725 patent, claim 6 of the '424 patent, and claims 1, 2, and 6 of the '219 patent, are invalid under the on-sale bar." The Supreme Court affirmed the on-sale-bar holding in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 586 U.S. ___ (2019) (holding a sale need not be public to trigger the AIA on-sale bar). So claim 2 of the '725 patent was adjudicated invalid; claim 1 was not asserted in that case and was not part of that invalidity holding.
• IPRs: the GreyB database shows IPR petitions against family members US 8,598,219, US 8,729,094, and US 9,173,942, each with institution denied (2014–2016). No IPR listing was found specifically for 7,947,725.
• CAFC 2026 dockets: no 2026 Federal Circuit appeal, order, or docket referencing 7,947,725 was located. The 2016–2019 appeals above (No. 16-1284 and the Supreme Court cert. proceeding) are the last appellate activity I can attribute to this patent.

5. Uncertainty / caveats

1. I could not verify the current expiry date discrepancy (Jan. 30, 2024 base / Jul. 30, 2024 with pediatric exclusivity per Orange Book, vs. "2025-07-21" anticipated expiration per Google Patents).
2. I did not independently confirm the outcome or abandonment of the 2013 reissue application on this patent.
3. My conclusion of no 2026 CAFC activity rests on general web searching, not a direct CAFC docket query; treat it as "not found."
4. I have kept 7,947,724 and 7,960,424 distinct from 7,947,725 throughout, as requested — they are separate sibling patents in the same family and are frequently cited together, but no results for those numbers are substituted for the '725 patent here.

I'll research litigation involving US 7,947,725. Let me search multiple sources.

Let me gather more details on specific cases and outcomes.

Let me get more detail on the Delaware cases and remaining dockets.

Litigation Involving U.S. Patent No. 7,947,725

Important framing note: U.S. 7,947,725 (the "'725 patent," Liquid pharmaceutical formulations of palonosetron) is one member of the Helsinn/Roche Aloxi® (palonosetron HCl) patent family. In virtually every case it was asserted together with its sibling patents — 7,947,724 (the '724), 7,960,424 (the '424), 8,598,219 (the '219), 8,729,094 (the '094), and sometimes 8,518,981 ('981), 8,598,218 ('218). Because the family was litigated as a bloc, many public litigation databases list cases under the sibling numbers. Below I list the proceedings where the '725 patent is documented as asserted or implicated, and flag where the record is uncertain.

1. The Lead Hatch‑Waxman Case — D.N.J.

Helsinn Healthcare S.A. and Roche Palo Alto LLC v. [Dr. Reddy's Laboratories, Ltd.](/litigations/by-defendant/Dr.%20Reddy's%20Laboratories%2C%20Ltd.); Dr. Reddy's Laboratories, Inc.; Sandoz, Inc.; Teva Pharmaceuticals USA, Inc.; and Teva Pharmaceutical Industries, Ltd.

• Court / Case No.: U.S. District Court for the District of New Jersey, Civil Action No. 11‑3962 (MLC)(DEA) (consolidated with Civ. Nos. 11‑5579 and 13‑5815)
• Filed: The initial complaint was filed in 2011; the consolidated action was tried in 2015.
• Patents asserted: '724, '725, '424, and '219. Claim 2 of the '725 patent was specifically asserted.
• Outcome / status:
  • Sandoz — dismissed by consent Dec. 31, 2014 (Dkt. 247); settled.
  • Dr. Reddy's — dismissed on stipulation Oct. 16, 2015 (Dkt. 355); settled (settlement permitted launch on or after Sept. 30, 2018 or earlier in certain circumstances).
  • Teva — remained; 11‑day bench trial June 2015, closing arguments Aug. 12, 2015.
  • Nov. 13, 2015 Memorandum Opinion / Nov. 16, 2015 Final Judgment: The asserted claims of the '724, '725, and '424 patents were held valid and infringed by both of Teva's proposed products (0.25 mg/5 mL and 0.075 mg/1.5 mL); the '219 claims were valid and infringed only by the 0.25 mg product. FDA approval of Teva's ANDA No. 090713 was made effective no earlier than July 30, 2024 (patent expiration + pediatric exclusivity).
  • Sources: Final Judgment PDF (Finnegan) — https://www.finnegan.com/a/web/56544/2G4oFc/20151116_311cv03962_helsinn_v_teva_di361_judgment.pdf ; Memorandum Opinion — https://www.finnegan.com/a/web/56530/2G4oFc/20151113_311cv03962_helsinn_v_teva_di360_memorandum_opinionpd.pdf

2. The Appeal — Federal Circuit

Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc.

• Court / Nos.: U.S. Court of Appeals for the Federal Circuit, Nos. 2016‑1284 and 2016‑1787
• Decision: May 1, 2017 — 855 F.3d 1356 (Fed. Cir. 2017). The panel reversed the district court, holding the asserted claims of the patents (including the '725 patent) invalid under the on‑sale bar of 35 U.S.C. § 102 (the 2001 MGI Pharma license/supply agreements) and therefore not infringed by Teva.
• Rehearing: Petition for rehearing en banc denied Jan. 16, 2018 (2018 WL 1583031).
• Sources: https://www.eisai.com/news/2018/pdf/enews201804pdf.pdf ; https://www.courtlistener.com/docket/[4493898](/patent/4493898)/38/helsinn-healthcare-sa-v-teva-pharmaceuticals-usa-inc/

3. The Supreme Court — Groundbreaking On‑Sale Bar Ruling

Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc.

• Court / No.: Supreme Court of the United States, No. 17‑1229 (586 U.S. ___)
• Argued: Dec. 4, 2018; Decided: Jan. 22, 2019
• Holding: Unanimous opinion by Justice Thomas affirming the Federal Circuit. The AIA's "on sale" language retained its settled pre‑AIA meaning, so a "secret sale" to a third party (the MGI agreements) can invalidate a patent. The '725 patent claims therefore remained invalid.
• Sources: https://supreme.justia.com/cases/federal/us/586/17-1229/ ; https://wolfgreenfield.com/ip-alerts/supreme-court-issues-decision-in-helsinn-v-teva

Practical effect: Teva launched its generic palonosetron "at‑risk" on March 23, 2018, after the Federal Circuit ruling and denial of rehearing; Helsinn's motion to enjoin the launch was denied.

4. Delaware District Court Cases Asserting the '725 Patent

DrugPatentWatch's patent‑specific litigation list for 7,947,725 and the record confirm the following D. Del. actions (https://www.drugpatentwatch.com/p/alphasignals/litigation/patent/7947725):

Note: DrugPatentWatch's public listings for '688 have been labeled both "Cipla" and "Aurobindo" across snapshots; the Supreme Court Joint Appendix ties D. Del. 13‑688 to an Aurobindo Paragraph IV notice dated Mar. 5, 2013.

5. New Jersey Cases (beyond the lead case)

The Google Patents litigation tab for US 7,947,725 lists numerous D.N.J. filings (https://patents.google.com/patent/US7947725/en). Many of these are later‑filed ANDA/505(b)(2) actions against additional sponsors, several of which settled:

• 3:11‑cv‑05579, 3:13‑cv‑05815, 2:16‑cv‑00173, 3:16‑cv‑00173, 3:16‑cv‑00681, 2:16‑cv‑04239, 3:15‑cv‑01228, 3:15‑cv‑02077, 3:15‑cv‑02078, 3:15‑cv‑07015, 3:15‑cv‑08132, 3:17‑cv‑03216, 2:17‑cv‑03216 — all D.N.J., various sponsors.
• Hospira: Helsinn also sued Hospira in D.N.J. (3:15‑cv‑02077), where Hospira moved to dismiss for lack of personal jurisdiction; the court's opinion addressed the '725 patent among others (https://cases.justia.com/federal/district-courts/new-jersey/njdce/3:2015cv02077/[316695](/patent/316695)/86/0.pdf).
• Sagent Pharmaceuticals: Helsinn filed 2:16‑cv‑00173 (Jan. 11, 2016) and 2:16‑cv‑00681 (Feb. 8, 2016), both asserting the '725 patent. Sagent later moved to enforce its settlement agreement.

Per Sagent's briefing, Helsinn filed infringement actions against at least fifteen other ANDA sponsors; Aurobindo, Akorn, Qilu, Somerset Therapeutics, and Fresenius Kabi had settled, with others litigating.

6. PTAB Proceedings (for context)

No IPR/PGR was filed directly against the '725 patent in the searches performed; the PTAB challenges in this family targeted 8,598,219 (PGR by Accord Healthcare, filed 2014‑09‑02), 8,729,094 (IPR2015‑01550/01554 by Dr. Reddy's, terminated Oct. 14, 2015 on settlement), and 9,173,942 (PGR by Dr. Reddy's, 2016). These are sibling patents, not the '725.

Bottom Line / Current Status

The '725 patent was asserted in multiple Hatch‑Waxman suits — most prominently the consolidated D.N.J. action 11‑3962 (Helsinn/Roche v. Dr. Reddy's, Sandoz, Teva) and numerous D. Del. actions (Aurobindo, Bedford/Ben Venue, Cipla, Mylan, Hospira, Par, Fresenius Kabi) plus later D.N.J. suits (Sagent and others). District courts initially upheld the '725 claims as valid and infringed, but the Federal Circuit (855 F.3d 1356, 2017) and the Supreme Court (No. 17‑1229, Jan. 22, 2019) held them invalid under the on‑sale bar based on Helsinn's 2001 confidential agreements with MGI Pharma. Most of the co‑defendant cases settled and were dismissed in 2014–2018. According to the Google Patents record, the '725 patent expired (anticipated expiration July 21, 2025, "Expired – Lifetime"), with a certificate of correction (2013) and a reissue application filed (2013) noted in the legal events.

Caveats and limits of this answer (per operating rules):

1. I could not retrieve a complete, authoritative docket‑by‑docket table for every case; the Delaware and New Jersey case lists above are drawn from DrugPatentWatch, Google Patents' litigation tab, and court PDFs, which sometimes mislabel which sibling patent was asserted in a given suit.
2. Where I state a case "settled," that reflects termination by stipulation/consent in the record; the actual settlement terms are generally confidential.
3. I did not verify each docket on PACER directly. If you need certified docket data for a specific case number, that should be pulled from PACER/RECAP.
4. I did not auto‑correct any patent numbers; each identifier is reported as it appears in the sources.

I'll verify the empty structured list against public sources before reporting.

Let me dig specifically into whether any IPR named the '725 patent itself.

Let me check a couple of remaining possibilities: a reissue (noted in the patent's legal events) and any aggregator-filed challenges.

Proceedings overview

The structured "PTAB proceedings on file" block is authoritative here, and it reports zero AIA trial proceedings on US 7,947,725 — no IPR, no PGR, no CBM; no institution decisions, no Final Written Decisions, no settlements, no terminations, and no PTAB appeals. My independent searching (PTAB E2E/PTABCTS petition records, Docket Alarm PTAB dockets, litigation-bulletin IPR/litigation trackers, and the family file histories) turned up nothing contradicting that — I found no petition that names the '725 patent as the challenged patent. So the bottom line for a defendant is not "the patent survived IPRs and is hardened," and it is also not "the PTAB killed it." Rather: *the invalidity work on this patent was done in Article III — the only claim Helsinn ever asserted in the Hatch-Waxman case (claim 2) was held invalid under the pre-AIA on-sale bar, 35 U.S.C. § 102(b), by the Federal Circuit in Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017), and the Supreme Court affirmed 9–0 — and the patent has since expired (anticipated expiration 2025-07-21, per the Google Patents legal-status record, "Expired – Lifetime").* For a 2026 assertion letter, that combination is dispositive long before any PTAB question arises.

Because the prompt's per-proceeding template cannot be populated for proceedings that do not exist, I use it below only for the family-adjacent PTAB matters (which do not name the '725) and for the Article III proceedings that actually decided the '725's fate. I have kept those clearly segregated so no reader mistakes them for IPRs on this patent.

NON-PROCEEDING — No AIA trial on US 7,947,725 (canonical ODP result)

• Type: N/A — no IPR / PGR / CBM on file.
• Filed: N/A.
• Status: No proceeding. Consistent with the ODP result; corroborated by my searches of PTAB petition/decision records and litigation trackers.
• Judge panel: N/A.
• Petition grounds: N/A.
• Institution decision: N/A.
• Final Written Decision: N/A.
• Settlement / termination: N/A.
• Appeal: N/A.
• Why there is nothing (structural explanation): IPR grounds are confined by 35 U.S.C. § 311(b) to §§ 102/103 "only on the basis of prior art consisting of patents or printed publications." The theory that actually defeated this patent family — the April 2001 Helsinn–MGI Supply and Purchase Agreement as an on-sale bar — is categorically unavailable in an IPR. PGR is unavailable because the '725 patent is pre-AIA (effective filing date 2003-01-30 / 2004-01-30, well before 2012-03-16), and CBM is unavailable because a pharmaceutical formulation patent is not a "covered business method" patent. So a would-be petitioner in 2013–2016 was left with the § 103 obviousness and § 112 written-description theories that had already failed in the district court. That is the most likely reason an asserted patent with 15+ ANDA defendants generated no IPR on the '724/'725/'424 group.
• Defensive value: A missing-IPR signal here is not a sign of a strong patent. The absence is explained by the mismatch between the winning invalidity theory (on-sale bar, IPR-unavailable) and the IPR forum, not by the patent's resilience. Do not present "no IPRs" as evidence of validity.

Family-adjacent PTAB activity (does NOT name the '725 — create NO estoppel as to it)

The palonosetron formulation family did draw PTAB petitions — but on the later-issued siblings. These are worth knowing because opposing counsel may conflate them.

IPR2015-01550, IPR2015-01551, IPR2015-01553, IPR2015-01554 — [Dr. Reddy's Laboratories, Ltd.](/litigations/by-defendant/Dr.%20Reddy's%20Laboratories%2C%20Ltd.) & Inc. v. Helsinn Healthcare S.A. & Roche Palo Alto LLC

• Patent challenged: U.S. 8,729,094 (a later family member), not the '725.
• Filed: 2015-07-03 (per the '094 petition of record; e.g., https://www.docketalarm.com/cases/PTAB/IPR2015-01554/).
• Grounds: principally § 103 obviousness over 5-HT₃-antagonist and palonosetron prior art (Eglen 1995, Tang 1998, the Berger '333 patent, antiemetic guidelines, etc.) — the same clinical/obviousness theory Helsinn defeated at trial.
• Status/outcome: Not confirmed from the sources I retrieved; verify each on PTAB E2E (https://ptacts.uspto.gov/ptacts/). I will not guess at institution or FWD results.
• Defensive value as to the '725: none. IPR estoppel under § 315(e)(2) is patent- and claim-specific; an '094 IPR neither invalidates nor estops anything about the '725.

PGR2016-00007 and PGR2016-00008 — Dr. Reddy's Laboratories, Ltd. & Inc. v. Helsinn Healthcare S.A.

• Patent challenged: U.S. 9,173,942.
• Filed: on or about 2016-02-05 (reported in Generically Speaking (Spring 2016) ANDA/new-proceeding table).
• Record evidence: Dr. Reddy's petition and Helsinn's Patent Owner Preliminary Response are in the PTABCTS file (e.g., petition file at https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1458462](/patent/1458462)), arguing the Petition failed to show a POSA would have selected palonosetron or the 0.25 mg / 0.05 mg/mL dose.
• Status/outcome: Not confirmed from the sources I retrieved; verify on PTAB E2E.
• Defensive value as to the '725: none (different patent, and PGR findings create no estoppel against '725).

PGR2014-00010 — terminated 2014-11-24. This termination is cited in the family file history, but the patents listed around it are other family members; I could not confirm from the retrieved records which patent PGR2014-00010 challenged, and I will not assert that it targeted the '725. Confirm before relying on it.

Article III proceedings that actually decided the '725 (for context — these are not PTAB matters)

Helsinn Healthcare S.A. et al. v. Dr. Reddy's Labs., Ltd. et al., Civ. No. 11-3962 (MLC) (D.N.J.) — judgment entered on/after 2015-11-13

• Asserted claims: claims 2 and 9 of the '724 patent, claim 2 of the '725 patent, claim 6 of the '424 patent, and claims 1, 2, 6 of the '219 patent.
• Holding (Cooper, J., 2015-11-13): all asserted claims valid and infringed; on-sale bar proved as to the "sale" prong but not proved as to "ready for patenting." Opinion: https://www.finnegan.com/a/web/56530/2G4oFc/20151113_311cv03962_helsinn_v_teva_di360_memorandum_opinionpd.pdf

Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., Nos. 2016-1284 et al. (Fed. Cir. 2017-05-01), 855 F.3d 1356

• Disposition: reversed. The asserted claims of the '724, '725, and '424 patents are invalid under pre-AIA § 102(b) (the MGI Supply and Purchase Agreement was a commercial sale/offer for sale; the invention was ready for patenting); the '219 patent claims were likewise held invalid under the AIA on-sale bar.
• Helsinn petitioned for en banc rehearing on 2017-06-30.

Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., No. 17-1229 (U.S. 2019-01-22), 139 S. Ct. 628

• Certiorari granted 2018-06-25; affirmed — the AIA did not change the on-sale bar's reach to sales whose terms do not publicly disclose the invention. Opinion: https://www.supremecourt.gov/opinions/18pdf/17-1229_l5gm.pdf

Post-grant USPTO paper trail on the '725 itself (not an AIA trial): the Google Patents legal-events record shows a certificate of correction (2013-05-14) and a reissue application filed (event code "RF," effective date 2013-05-22). I could not confirm the disposition of that reissue from the sources retrieved — a defendant should pull the '725 file wrapper on Patent Center to confirm whether a reissue patent issued (which would alter claim numbering and could restart exposure as to reissued claims).

Strategic summary

Claim status on the '725. The patent has exactly two claims. Claim 2 (0.05 mg/mL palonosetron HCl, pH 4.5–5.5, 0.005–1.0 mg/mL EDTA, 10–80 mg/mL mannitol) is the claim Helsinn asserted in the Hatch-Waxman action, and it has been held invalid for the on-sale bar — reversed by the Federal Circuit and affirmed by the Supreme Court. Claim 1 (0.03–0.2 mg/mL, pH 4–6, tonicifying mannitol, 0.005–1.0 mg/mL EDTA) does not appear to have been the subject of a final validity adjudication in the case that reached the Supreme Court (that case recited "claim 2 of the '725 patent" as the asserted claim), although at least one later D.N.J. claim-construction filing in the ALOXI® litigation recited "claims 1 and 2 of the '725 patent" as asserted (see the recap at https://storage.courtlistener.com/recap/gov.uscourts.njd.[261662](/patent/261662).88.0.pdf). I could not confirm a final adjudication of claim 1, so treat claim 1 as formally untested rather than canceled — but note that its invalidity would follow the same on-sale-bur analysis as claim 2, since the Fed. Cir. ruling was directed to "the asserted claims of the '724, '725, and '424 patents" as a group on a common § 102(b) ground.

Estoppel landscape. There is no § 315(e)(2) estoppel against anyone as to the '725, because no IPR reached a final written decision on it. The '094 and '942 proceedings generate no estoppel as to this patent. Practically, the estoppel question is academic: (i) the patent expired 2025-07-21 (Google Patents "Expired – Lifetime," anticipated expiration 2025-07-21), so there is no prospective injunctive exposure, only possible past-damages exposure under the 35 U.S.C. § 286 six-year lookback (i.e., conduct on or after 2020-09-27, much of which post-dates the Fed. Cir. invalidity ruling the Supreme Court affirmed in 2019); and (ii) any IPR on an expired patent would be a purely academic exercise with no practical payoff. Any defendant served long ago is also well past the § 315(b) one-year bar.

Pattern signals. (1) No defensive aggregator — Unified Patents and similar entities do not appear anywhere in this chain; the only PTAB filings were by a directly interested ANDA defendant, Dr. Reddy's. (2) The patent owner went 0-for-1 on the merits in the tribunal that mattered: Helsinn won at the district court on obviousness and written description, then lost the entire formulation family on the on-sale bar at the Federal Circuit, and lost again at the Supreme Court (9–0). (3) Helsinn litigated aggressively — 15+ ANDA defendants across D.N.J. and D. Del. — and settled with Dr. Reddy's, Sandoz and others with generic entry no earlier than 2018-09-30, while Teva launched at risk on 2018-03-23. (4) On the PTAB side, the family's ONLY activity was against the later-issued '094 and '942 patents, not the '724/'725/'424 group that carried the Orange Book listings.

Recommended next steps

1. If you are a defendant facing an assertion of the '725 today, lead with the Article III record, not the PTAB record. Quote the Federal Circuit's disposition: the asserted claims of the '724, '725, and '424 patents are invalid under pre-AIA § 102(b), 855 F.3d 1356 (Fed. Cir. 2017), aff'd, 139 S. Ct. 628 (2019) — full text at https://www.supremecourt.gov/opinions/18pdf/17-1229_l5gm.pdf. Then note the expiry: the patent's anticipated expiration was 2025-07-21.
2. Do not assert that the PTAB decided anything about this patent. It did not. Any representation to the contrary (whether from the other side or in your own papers) is wrong. If you need to say something about PTAB activity, say: "no AIA trial proceeding has ever been instituted on US 7,947,725."
3. Pull the '725 file wrapper on Patent Center to resolve the two open items I could not confirm from public sources: (a) the disposition of the 2013 reissue application (event "RF," effective 2013-05-22) — if a reissue patent issued, the claims and numbering you must analyze may differ from the '725 as granted; and (b) whether any ex parte reexamination certificate exists (none appears in the record I retrieved, but the wrapper is definitive).
4. Confirm scope of the invalidity ruling as to '725 claim 1 by checking whether the later D.N.J. action (CourtListener recap njd.261662) reached judgment, and on what ground. If claim 1 was adjudicated on the same § 102(b) theory, it is equally dead; if not, it is "untested," and you should assume the patent owner could argue it survived — but even then, the 2025-07-21 expiry caps that argument.
5. Check the expiration arithmetic yourself against the Orange Book and the Patent Term Adjustment/extension certificates. I am relaying the "2025-07-21 anticipated expiration / Expired – Lifetime" entries from the Google Patents record. My searches also surfaced an FDA tentative-approval letter listing a 2024-07-30 date (with pediatric exclusivity) for the '724 patent — i.e., a date associated with the sibling, not necessarily the '725. Reconcile the two before you put an expiry date in a letter.

Confidence and gaps. High confidence: zero AIA trials on the '725; the Fed. Cir. invalidity judgment and SCOTUS affirmance; the expiry status. Lower confidence (verify): the outcomes/statuses of IPR2015-01550/-01551/-01553/-01554 and PGR2016-00007/-00008; the target patent of PGR2014-00010; the disposition of the '725 reissue; and whether '725 claim 1 was ever finally adjudicated. I did not fabricate any proceeding number or outcome, and I declined to state results I could not verify.

I'll verify the assignment records against the USPTO Assignment Center and cross-reference litigation/ownership context.

Let me try to retrieve the recorded correspondents and confirm the assignment entries.

Ownership & Assignment Analysis — US 7,947,725 B2

"Liquid pharmaceutical formulations of palonosetron" · App. 11/388,268 · filed 2006‑03‑24 · granted 2011‑05‑24 · priority 2003‑01‑30 · current status: Expired – Lifetime (anticipated expiration 2025‑07‑21 per Google Patents legal events)

Sourcing note / limitation. Every reel/frame entry below is taken from the Google Patents legal‑events record for US 7,947,725, which mirrors the USPTO Assignment Center entries, plus USPTO PEDS/ODP and court filings. The tooling available to me could not retrieve the correspondent-of-record field for these reels (Assignment Center is an interactive search UI; no API response was obtainable). I therefore mark correspondents "not retrieved" rather than guess. Anyone verifying should open https://assignmentcenter.uspto.gov/ (or https://assignment.uspto.gov/patent/index.html) and search patent number 7947725, then read the correspondent attorney/firm off each reel. I also flag one legal event below that I could not independently confirm.

Inventors

Pattern notes (not a fire-sale precursor, but two findings worth the record):

1. Split-household inventorship (5 Helsinn / 3 Roche). The patent is the product of Helsinn's in-licensed development sitting on top of Roche/Syntex's Phase I–II work. This is why the chain of title runs in two parallel tracks that only merge in 2016.
2. The Roche-side inventor assignment was executed 4.3 years after filing. Helsinn's five inventors signed 2006‑06‑08 (2.5 months post-filing). The three Roche inventors did not sign until 2010‑07‑26 to 2010‑07‑29 — roughly ten months before grant and roughly twelve months before the first infringement complaints. Late-executed confirmatory assignments of this kind are typically obtained to cure an incomplete chain of title in anticipation of enforcement. It is a prosecution/enforcement tell, not an NPE tell. There is no evidence any inventor departed the assignees.
3. Inventor Malefyt straddled both sides (Roche/Syntex inventor; Helsinn consultant), which is consistent with the licensed-in nature of the program rather than anything irregular.

Original assignee

Named on the face of the issued patent: Helsinn Healthcare S.A. (Lugano, Switzerland) and Roche Palo Alto LLC (the Syntex (U.S.A.) Inc. successor entity).

• Helsinn Healthcare S.A. — Swiss, family-owned/family-run pharmaceutical group (Braglia family). At the relevant time its model was explicitly business-to-business in-licensing: it took in-licensed new chemical entities, ran development, and partnered for distribution; it had no U.S. sales force and no in-house formulation R&D labs (it used CROs/CMOs such as Oread). Status: operating — co-owned today by Helsinn Advanced Synthesis SA, Helsinn Birex Pharmaceuticals Ltd (Ireland) and Helsinn Therapeutics (U.S.), Inc.
• Did they ship a product embodying the claims? Yes. Example 4 of this patent is the Aloxi® (palonosetron HCl injection) formulation; Helsinn owns NDA 021372, marketed in the U.S. by Eisai Inc. with co-promotion by Helsinn Therapeutics (U.S.), Inc. This patent was Orange‑Book listed for Aloxi.
• Roche Palo Alto LLC — at filing, an operating pharma R&D subsidiary of Roche Holding. Roche had discontinued its palonosetron program at the end of Phase II (1997) and licensed the program (plus remaining API batches) to Helsinn in early 1998 for ~$10M. Roche's current status: operating (Roche group entity); its palonosetron economic stake in this patent was divested to Helsinn in 2016.

Important adjudicated-status caveat: this patent was held invalid under the pre‑AIA on‑sale bar by the Federal Circuit in Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017), and the Supreme Court affirmed the AIA portion of that judgment in 586 U.S. ___ (2019) (139 S. Ct. 628). Helsinn's 2001 MGI Pharma license/supply agreements triggered the bar. Verify against the opinion before relying on enforceability.

Assignment timeline

No recorded assignment exists in the USPTO system that would put this patent in the hands of a third-party acquirer. Every recorded conveyance is either an inventor-to-employer original assignment or an intra-Helsinn/Roche title normalization.

• 2006‑06‑08 (executed) / recorded 2011‑02‑16 — Reel 025819 / 0244

  • Conveyance: Assignment (original inventor assignment)
  • Assignor: Calderari, Bonadeo, Cannella, Enrico Braglia, Riccardo Braglia (individuals)
  • Assignee: Helsinn Healthcare SA (Switzerland)
  • Correspondent: not retrieved — recommend checking this reel in Assignment Center
  • Context: original inventor-to-employer title, executed 2.5 months after filing but not recorded until 2011.

• 2010‑07‑26 / 2010‑07‑29 (executed) / recorded 2011‑02‑16 — Reel 025819 / 0334

  • Conveyance: Assignment (original inventor assignment, late-executed)
  • Assignor: Andrew Miksztal, Thomas Malefyt, Kathleen M. Lee (individuals)
  • Assignee: Roche Palo Alto LLC (California)
  • Correspondent: not retrieved — recommend checking this reel
  • Context: chain-of-title perfection on the Roche side ~10 months before grant and ~12 months before suit; the reason this patent issued as jointly assigned.

• 2016‑05‑11 (executed and recorded) — Reel 038544 / 0269

  • Conveyance: Assignment
  • Assignor: Roche Palo Alto LLC
  • Assignee: Helsinn Healthcare SA (Switzerland)
  • Correspondent: not retrieved
  • Context: consolidation of 100% ownership in Helsinn — Roche exits this patent entirely, five years after grant and after Roche had co-litigated the ANDA cases as a named co-plaintiff. This is the Roche program wind-down, not a sale to an asserter.

• 2018‑08‑23 (executed) / recorded 2018‑11‑14 — Reel 047534 / 0024

  • Conveyance: Assignment — recorded as a "PATENT CO-OWNERSHIP AGREEMENT"
  • Assignor: Helsinn Healthcare SA
  • Assignee: Helsinn Advanced Synthesis SA + Helsinn Birex Pharmaceuticals Ltd + Helsinn Therapeutics (U.S.), Inc. (co-owners)
  • Correspondent: not retrieved
  • Context: internal group reorg / co-ownership split among three operating Helsinn companies (API synthesis, finished-dose manufacturing in Ireland, U.S. commercialization). No external party introduced.

• 2018‑08‑23 (executed) / recorded 2018‑11‑21 — Reel 047617 / 0285

  • Conveyance: Corrective Assignment (correcting assignee name spelling — "Helsinn Birex Pharmaceuthials/Pharmaceuticals" — and assignee addresses previously recorded on Reel 047534 Frame 0024)
  • Assignor: Helsinn Healthcare SA
  • Assignee: same three Helsinn co-owners
  • Correspondent: not retrieved
  • Context: correction of record only — same transaction as 047534/0024, re-recorded 7 days later.

• 2022‑12‑30 (executed and recorded) — Reel 062254 / 0888

  • Conveyance: Security Interest (not an assignment of title)
  • Assignor: Helsinn Healthcare SA, Helsinn Therapeutics (U.S.), Inc., Helsinn Birex Pharmaceuticals Limited
  • Assignee (secured party): Hamilton SA LLC (New York)
  • Correspondent: not retrieved
  • Context: securitization / financing — a lender taking a collateral lien over the Helsinn group's IP, including this patent. Title does not move.

• 2023‑09‑18 (executed) / recorded 2023‑09‑20 — Reel 064961 / 0567

  • Conveyance: Release by Secured Party ("Release of Security Interest")
  • Assignor: Hamilton SA LLC
  • Assignee: Helsinn Healthcare SA, Helsinn Therapeutics (U.S.), Inc., Helsinn Birex Pharmaceuticals Limited
  • Correspondent: not retrieved
  • Context: lien satisfaction/discharge — the 2022 collateral interest is released; the patent returns to unencumbered Helsinn ownership.

Additional USPTO legal events (not assignments, for completeness): 2013‑05‑14 Certificate of Correction; 2013‑08‑13 "Reissue application filed" (effective 2013‑05‑22); maintenance fees paid at 4 yrs (2014‑10‑23), 8 yrs (2018‑10‑25) and 12 yrs (2022‑10‑20). ⚠️ I could not independently verify the scope or disposition of the 2013 "reissue application filed" event — treat it as unconfirmed and check the PEDS/PatentCenter transaction history.

Post-issuance litigation posture (for the pre-litigation-transfer test): Helsinn + Roche sued Dr. Reddy's, Sandoz and Teva in D.N.J. in July 2011 (2:11‑cv‑03962 and consolidated 3:2011‑cv‑05579), roughly seven weeks after grant. Google Patents also lists Delaware ANDA cases (1:13‑cv‑00688, 1:13‑cv‑01612, 1:13‑cv‑02101, 1:14‑cv‑00709, 1:15‑cv‑00264/00265/00865). All venues are normal Hatch‑Waxman/Venue‑Act fora for the defendants' home districts — no E.D. Tex. or W.D. Tex. venue-shopping signature.

Timeline diagram

timeline
    title Ownership of US 7947725
    2003 : Priority application filed
    2006 : US application 11 388 268 filed
         : Helsinn inventors assign to Helsinn
    2010 : Roche inventors assign to Roche Palo Alto
    2011 : Patent issues
         : Both inventor assignments recorded
         : First ANDA suits filed in D NJ
    2016 : Roche stake assigned to Helsinn
    2018 : Co ownership split among three Helsinn units
    2022 : Security interest granted to Hamilton SA LLC
    2023 : Security interest released
    2025 : Anticipated expiration

NPE / troll-pattern signals

1. Shell-entity transfer — not present.
Every assignee is an operating pharmaceutical company: Helsinn Healthcare SA (parent), Helsinn Advanced Synthesis SA (API manufacturing), Helsinn Birex Pharmaceuticals Ltd (finished-dose plant, Ireland), Helsinn Therapeutics (U.S.), Inc. (US commercial entity), Roche Palo Alto LLC. None carries an "IP / Licensing / Holdings / Ventures" suffix, and none is a single-member Delaware/Texas LLC at a registered-agent address. The 2018 transfer (Reel 047534/0024, corrected by 047617/0285) is a co-ownership split among existing Helsinn operating subsidiaries, not a move to a licensing vehicle.

2. Known asserter in the chain — not present.
No assignee or assignor matches any public NPE list (Acacia, Marathon, Intellectual Ventures, IPNav, Wi‑LAN, Mosaid/Conversant, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation Corp, Spangenberg entities). The chain is Roche → Helsinn and then wholly inside the Helsinn group. The only third party ever in the title chain besides the two originators is Hamilton SA LLC (Reel 062254/0888) — and that is a security interest / collateral lien, released at Reel 064961/0567, not a transfer of title.

3. Repeat correspondent across the chain — unclear (data not obtained).
This is the single metric I could not compute, because the correspondent-of-record is not exposed in the sources I could reach. Action item: pull the correspondent for Reels 025819/0244, 025819/0334, 038544/0269, 047534/0024, 047617/0285, 062254/0888, 064961/0567. Two things to look for: (a) one law firm handling all of them, which would be expected for a single family's global IP counsel and is not a finding by itself; (b) whether a non‑Helsinn/non‑Roche firm appears only on the 2016 Roche divestiture or the 2022 lien — that would merit a second look. Marked unclear, no inference drawn.

4. Cascading transfers — not present.
There are four substantive conveyance events across nineteen years (2006/2010 inventor assignments → 2016 Roche exit → 2018 internal co-ownership → 2022 lien/2023 release). No consecutive hops through chained LLCs, no clustering inside 24 months, no shared-principal pattern. The 2018 pair (047534/0024 on 2018‑11‑14; 047617/0285 on 2018‑11‑21) is a recording plus its own correction of the same transaction, 7 days apart — explicitly flagged in the record as a corrective assignment for a misspelled assignee name and wrong addresses — not a cascade.

5. Pre-litigation transfer — present in timing, benign in substance.
Both inventor assignments were recorded 2011‑02‑16, about five months before the first complaints (July 2011). That is inside the 6‑month window. However, this was the original owners perfecting title from their own inventors — the executions are 2006‑06‑08 (Helsinn) and 2010‑07‑26/29 (Roche) — not a transfer to an asserter to engineer venue or standing. Recording a complete chain of title immediately before a Hatch‑Waxman filing is routine practice. Flagged for completeness; not an NPE indicator.

6. Bankruptcy fire-sale — not present.
No Chapter 7/11 anywhere in the chain. Roche's exit from palonosetron was a voluntary 1997–98 program discontinuation and out-license (~$10M) that long predates this patent, and its equity stake here was assigned out in 2016 (038544/0269) from a solvent parent. No 363 sale, no auction.

7. Privateering — not present.
The inverse of privateering is present: Roche remained a named co‑owner and co‑plaintiff through the 2011–2015 D.N.J. Hatch‑Waxman litigation rather than operating through a proxy NPE, and then conveyed its stake to its co-owner Helsinn in 2016. Roche asserted directly, in its own name.

8. Defensive aggregator — not present.
The chain terminates at Helsinn Birex / Helsinn Advanced Synthesis / Helsinn Therapeutics (U.S.) and is encumbered-then-released to the same group. No RPX, AST, LOT, Unified Patents or OIN involvement.

Verdict

Operating-company assertion.

Helsinn Healthcare S.A. and Roche Palo Alto LLC were the original joint assignees (Reel 025819/0244 and 025819/0334), the patent issued to them on 2011‑05‑24, and Example 4 of the specification is the Aloxi® product Helsinn actually commercialized, NDA 021372. Title moved only twice in substance — Roche's 2016 consolidation into Helsinn (Reel 038544/0269) and the 2018 intra-group co-ownership split (Reels 047534/0024 / 047617/0285) — with a 2022 financing lien (Reel 062254/0888) released in 2023 (Reel 064961/0567). Helsinn then sued the ANDA filers (Teva, Dr. Reddy's, Sandoz and ultimately ~15 more sponsors) as the operating NDA holder asserting against actual generic competitors, which is the paradigm operating-company assertion — not an NPE. The one NPE-shaped tell one might reach for, the 2016 Roche divestiture, is a co-owner exiting a program it had itself abandoned in 1997, five years after grant, in favor of its joint-venture partner. (Note the separate merits outcome: Helsinn v. Teva, 855 F.3d 1356 (Fed. Cir. 2017), aff'd 586 U.S. ___ (2019), held the asserted claims invalid under the on-sale bar — a validity loss, not an ownership/NPE finding.)

Verify here: https://assignmentcenter.uspto.gov/ (search patent 7947725) and https://assignment.uspto.gov/patent/index.html — with the specific open item being the correspondent-of-record on each reel, which I could not retrieve.

I'll research the prior art for US 7,947,725 specifically, starting with the most cited references and the palonosetron compound art.

Let me verify details on the key excipient-related prior art references.

Let me verify the commercial setron injectable formulations (ondansetron, dolasetron) that disclose the relevant excipients.

Prior Art Analysis — US 7,947,725 B2 (Liquid pharmaceutical formulations of palonosetron)

Search scope & method note: I have no direct API access to USPTO PatentCenter/PAIR or the Examiner's file wrapper in this session. The prior-art universe analyzed below is taken from (a) the authoritative full patent text supplied in your message — specifically the "Patent Citations (28)," "Citations (22)," and "Family Cites Families (16)" tables that Google Patents mirrors from the USPTO record — and (b) targeted live web searches used to confirm bibliographic data and content. Where the live record conflicts with anything, I flag it. Because the application was filed March 24, 2006 with priority to January 30, 2003, the pre-AIA (35 U.S.C. §§ 102/103 as they read before March 16, 2013) govern. The critical reference date is January 30, 2003 (with a January 30, 2002 § 102(b) one-year bar date).

0. A crucial framing point on "anticipation"

The task asks which reference anticipates under § 102. Applying the rule strictly — a single reference must disclose every element of the claim — no patent citation of record anticipates either claim. Both claims require the simultaneous presence of:

• palonosetron HCl at a defined low concentration (0.03–0.2 mg/mL; or exactly 0.05 mg/mL), and
• a sterile injectable aqueous carrier at pH 4–6 (or 4.5–5.5), and
• mannitol as a tonicifier, and
• EDTA at 0.005–1.0 mg/mL.

No single cited reference discloses palonosetron together with mannitol and EDTA at that pH. The invalidity that actually attached to this family was not § 102 reference anticipation but the § 102(b)/§ 102(a)(1) on-sale bar (Helsinn's 2001 agreements with MGI Pharma) — see § 5 below. I therefore classify each reference honestly as anticipatory (no reference qualifies), closely relevant § 103 art, or background.

1. The closest art — palonosetron-specific

(a) US 5,202,333 A — Tricyclic 5-HT3 receptor antagonists

• Full citation: U.S. Patent No. 5,202,333 (Berger, Clark, Smith, Weinhardt, Eglen), "Tricyclic 5-HT3 receptor antagonists," assigned to Syntex (U.S.A.) Inc. (later Roche Palo Alto LLC).
• Dates: filed (CIP) May 21, 1991; priority Nov. 27, 1989; granted April 13, 1993. (Google Patents/UPC lists a nominal expiration of 2015-04-12.)
• Description: Genus claim to tricyclic 5-HT3 antagonists including palonosetron (RS-25259-197); discloses pharmaceutical compositions and Example 13 — a representative IV formulation containing "Compound of Formula I 10–100 mg; Dextrose Monohydrate q.s. to make isotonic; Citric Acid Monohydrate 1.05 mg; Sodium Hydroxide 0.18 mg; Water for Injection to 1.0 mL," at pH 3.7. The specification also states the final composition may contain "0.000001% w to 10.0% w … preferably 0.00001% w to 1.0% w" of the compound.
• § 102 assessment: This is the single most relevant reference and the closest to the invention, but it does not anticipate either claim. It discloses palonosetron and an acidic injectable formulation but (i) uses dextrose (not mannitol) as the tonicifier, (ii) has no EDTA, and (iii) is at pH 3.7, outside the claimed pH 4–6. It is the foundational § 103 reference against which the '725 claims were measured (and the district court found the claims non-obvious over it, a holding the Federal Circuit reversed only on the on-sale bar, not on obviousness).
• Also note: U.S. Provisional 60/444,351 (Jan. 30, 2003) is the priority document, and US 5,567,818 A (Syntex, "Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de]isoquinolin-1-one derivatives," filed 1994-07-08) appears in the "Family Cites Families" list as related palonosetron-making art.

(b) WO 2003/100091 A1 — Means and methods for improved treatment using 'setrones'

• Full citation: PCT Publication WO 2003/100091 A1, Epidauros Biotechnologie AG.
• Dates: filed May 24, 2002; published Dec. 4, 2003.
• Description: Genetic/pharmacogenomic methods relating to setron (5-HT3 antagonist) therapy.
• § 102 assessment: Background only. Published after the Jan. 30, 2003 priority date; not § 102 prior art to the '725 claims, and discloses no formulation.

(c) WO 2004/045615 A1 and WO 2004/073714 A1 — Helsinn palonosetron-use applications

• WO 2004/045615 A1 (Helsinn Healthcare SA), "Palonosetron for the treatment of chemotherapy-induced emesis" — priority Nov. 15, 2002; published June 3, 2004.
• WO 2004/073714 A1 (Helsinn Healthcare S.A.), "Use of palonosetron treating post-operative nausea and vomiting" — priority Feb. 18, 2003; published Sept. 2, 2004.
• § 102 assessment: These are Helsinn's own later-filed applications and are not prior art to the '725 patent: their publication dates post-date the Jan. 30, 2003 priority date, and WO 2004/073714's priority (Feb. 18, 2003) is after the '725 priority. They appear in the citation list as related/sibling art. (Their U.S. counterparts surface elsewhere as US 2006/0074101 and US 2011/0178118.)

(d) US 2004/0147510 A1 (Landau et al.) — Palonosetron IV bolus

• Cited by respondents in the PTAB record (not on the face of the '725 patent) as teaching intravenous bolus administration of palonosetron. Relevant to the "single IV bolus over 10–60 seconds" disclosure in the specification but not anticipatory of the composition claims; at most § 103 context.

2. Setron formulation art — the § 103 backbone

These disclose the generic formulation technology (citrate buffer, acidic pH, mannitol/tonicifier, EDTA) applied to structurally and functionally related 5-HT3 antagonists.

US 6,294,548 B1 — Multidose vial formulations … granisetron hydrochloride

• Citation/assignee: U.S. 6,294,548 B1 (James et al.), Hoffmann-La Roche Inc.
• Dates: filed May 4, 1998; granted Sept. 25, 2001. (Sibling publication US 2001/0020029 A1, SmithKline Beecham.)
• Description: Stable aqueous multidose injectable granisetron formulations; the compound "is stable … over the pH range 2 to 7"; a citrate buffer is added to control pH to a target of 6 (limits 5–7); discusses tonicifying/antimicrobial systems and terminal autoclaving. Example injectable compositions use citric acid + sodium chloride, pH adjusted to 5 ± 0.1.
• § 102 assessment: Most relevant setron injectable art for the pH element. Does not anticipate (different API; no palonosetron; no EDTA/mannitol pair in the claimed ranges) but strongly supports § 103 on "citrate-buffered, mildly acidic 5-HT3 injectable."

US 5,854,270 A — Oral compositions containing ondansetron (Gambhir)

• Citation/assignee: U.S. 5,854,270 (Renu Gambhir), Glaxo Wellcome Inc. / Novartis. (EP counterpart EP 0 792 149 B1; WO 96/15786.)
• Dates: filed (PCT) Nov. 20, 1995; priority Nov. 22, 1994; granted Dec. 29, 1998.
• Description: Liquid oral ondansetron composition; sweetener (sorbitol); pH 2.0–5.0 (pref. 2.5–4.5); ondansetron 0.005–1% w/v (pref. 0.02–0.2%). Claim 1 is a liquid oral composition "characterised in that the sweetener comprises sorbitol and the pH … 2.0 to 5.0."
• § 102 assessment: No anticipation (different drug, oral not injectable, sorbitol not mannitol, no EDTA). Relevant § 103 art for the low-concentration + acidic-pH concept in a setron liquid.

US 5,952,749 A / US 5,578,628 A / US 5,240,954 A / US 5,578,632 A — Glaxo "Medicaments" family (Tyers et al.)

• Citations/dates: U.S. 5,952,749 (granted July 13, 1999); U.S. 5,578,628 (Nov. 26, 1996); U.S. 5,240,954 (Aug. 31, 1993); U.S. 5,578,632 (Nov. 26, 1996) — all Glaxo Group Limited; common priority June 25, 1985.
• Description: Ondansetron formulations and medical uses (nausea/vomiting, gastrointestinal dysfunction).
• § 102 assessment: Background/§ 103 context for ondansetron medicinal formulations; no palonosetron, no anticipatory disclosure.

US 5,344,658 A and US 5,622,720 A — Glaxo (Collin)

• Dates: filed June 28, 1989; granted Sept. 6, 1994 and April 22, 1997 respectively.
• Description: Ondansetron compositions/processes, including crystal-size reduction of ondansetron HCl dihydrate.
• § 102 assessment: Background; relevant only as evidence that acidic, buffer-stabilized setron solutions were conventional.

US 5,955,488 A and US 6,063,802 A — Glaxo Wellcome (Winterborn)

• Dates: filed Nov. 22, 1994; granted Sept. 21, 1999 and May 16, 2000.
• Description: Ondansetron freeze-dried (lyophilized) compositions for oral administration.
• § 102 assessment: Background on ondansetron formulation stability; not anticipatory.

US 4,906,755 A and US 5,011,846 A — Merrell Dow (dolasetron)

• Dates: filed Nov. 3, 1986 (granted March 6, 1990) and Feb. 23, 1988 (granted April 30, 1991).
• Description: Dolasetron-related quinolizinone esters and medicament compositions. (Commercial Anzemet® IV contained, per the 2001 PDR evidence cited in the PTAB record, mannitol ~38.2 mg/mL.)
• § 102 assessment: Relevant § 103 art for "injectable setron tonicified with mannitol in the 10–80 mg/mL range." Not anticipatory for a palonosetron-specific claim.

US 4,695,578 A / US 4,753,789 A — Glaxo (ondansetron compounds/uses)

• Dates: filed 1984-01-25 / 1985-06-25; granted 1987/1988.
• Description: Ondansetron (1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones) and nausea/vomiting methods.
• § 102 assessment: Background genus/utility art for setrons.

US 4,886,808 A / US 4,937,247 A / US 5,034,398 A — Beecham (granisetron genus)

• Dates: priority April 27, 1985; granted 1989/1990/1991.
• Description: Indazole carboxamide 5-HT3 antagonists (the granisetron chemical class).
• § 102 assessment: Background compound art.

3. General excipient/pharmaceutical-formulation art

US 5,272,137 A — Aqueous pharmaceutical suspension for pharmaceutical actives

• Citation/assignee: U.S. 5,272,137 (Blase & Shah), McNeil-PFC, Inc.
• Dates: filed Feb. 14, 1992; granted Dec. 21, 1993.
• Description: Xanthan-gum/microcrystalline-cellulose suspension system; buffered; preferred pH 4–10 (4–8).
• § 102 assessment: General formulation background. Not anticipatory. (Cite it as evidence of routine pH-buffered aqueous excipient practice.)

US 6,287,592 B1 — Aqueous drink composition comprising ibuprofen

• Citation/assignee: U.S. 6,287,592 B1 (Dickinson et al.), The Boots Company Plc.
• Dates: filed Dec. 10, 1996; granted Sept. 11, 2001.
• Description: Aqueous oral liquid dosage form technology.
• § 102 assessment: Background; not anticipatory.

US 6,284,749 B1 — Preservative system for topically administrable pharmaceutical compositions …

• Citation/assignee: U.S. 6,284,749 B1 (Castillo et al.), Alcon Manufacturing, Ltd.
• Dates: filed Oct. 27, 1998; granted Sept. 4, 2001.
• Description: Fatty-acid/amino-acid soap preservative system for topical solutions.
• § 102 assessment: Background on stabilization/preservative systems. Notably, the respondents in the family's PTAB/IPR briefing relied on the combination Berger ('333) + Castillo ('749) + Gambhir ('270), but Castillo adds nothing specific to the claimed palonosetron/mannitol/EDTA combination; it does not anticipate.

US 6,132,758 A — Stabilized antihistamine syrup (Munayyer et al., Schering)

• Dates: filed June 1, 1998; granted Oct. 17, 2000.
• Description: Stabilized liquid syrup (listed under "Family Cites Families").
• § 102 assessment: Background on liquid stabilization; not anticipatory.

US 2003/0095926 A1 — Buccal, polar and non-polar spray or capsule … (Dugger)

• Dates: priority Oct. 1, 1997; published May 22, 2003.
• Description: Buccal spray/capsule delivery of GI/urinary drugs.
• § 102 assessment: Background on alternative liquid delivery; not anticipatory.

Additional "Family Cites Families" formulation art (background only, not anticipatory)

• JPS 59-9539 B2 (Nippon Kayaku) — nitroglycerin aqueous solution and manufacturing method (filed Nov. 13, 1979; granted March 3, 1984).
• US 5,567,818 A (Syntex) — palonosetron intermediates (see §1(a)).
• US 5,576,317 A (Pfizer) — NK-1/5-HT3 antagonist combination for emesis.
• US 6,132,758 A (Schering) — antihistamine syrup (above).
• DE 198 33 119 A1 (Roche Diagnostics) — storage-stable injectable carvedilol (buffer + antioxidant + complexing agent) — general injectable-stabilization background.
• CN 1525856 A (Mitsubishi) — stable high-concentration pyrazolone injection.
• EP 512 400 / ATE 194 987 / GB 9305593 / ATA 156496 / GB 9721139 / KR 2003-0070073 / ES 2364046 / AU 2004204827 — pharmaceutical-use and formulation background.

None of these discloses palonosetron + mannitol + EDTA at pH 4–6; none anticipates.

4. Non-patent prior art of record (42 items)

Most relevant to the stability/oxidation rationale of the claims:

• Won, C.M. et al., "Photolytic and oxidative degradation of an antiemetic agent, RG 12915," International Journal of Pharmaceutics 121 (1995) 95–105. Discloses that a structurally related (quinuclidine-containing) 5-HT3 antiemetic undergoes photolytic/oxidative degradation (incl. N-oxide formation), and that lower drug concentration improves stability. This was a linchpin reference in the family's obviousness disputes — it teaches the "stability" motivation and the concentration-stability trend that the '725 claims exploit. § 103 art, not § 102 anticipation.
• Eglen, R.M. et al., Br. J. Pharmacol. 114:860–866 (1995) and Wong et al., Br. J. Pharmacol. 114:851–859 (1995) — pharmacological characterization of RS-25259-197 (palonosetron).
• Adis R&D Profile, Drugs in R&D Oct. 1999, 2(4):251–252; Stacher, Curr. Opin. Investig. Drugs 3(10):1502–1507 (2002); Navari, J. Supportive Oncology 1(2):89–103 (2003) — palonosetron development reviews.
• Tang, J. et al., Anesth. Analg. 87:462–467 (1998) and abstracts — RS-25259 dosing (relevant to low-concentration/dose art; cited in the sibling '094 IPR as teaching palonosetron IV concentrations of ~0.0005–0.14 mg/mL, overlapping 0.05 mg/mL).
• The 2001 PDR entries (ondansetron, granisetron, dolasetron injectables) — commercial setron injectables disclosing citrate buffer, pH ~3.3–4.0, mannitol (dolasetron 38.2 mg/mL) as conventional excipients. § 103 art.
• Textbook/formulary excerpts — Pharmaceutical Dosage Forms: Parenteral Medications (2d ed., Marcel Dekker 1992); Modern Pharmaceutics (2d ed. 1990); Theory and Practice of Industrial Pharmacy (3d ed. 1986, Lachman); Injectable Drug Development (Gatlin & Gatlin 1999); Yakuzaigaku Manual (Matsumoto, 1989); Barton "Citrate Buffer Calculation" (2000) — all establish that citrate buffers, acidic pH, tonicifiers and chelating agents were routine injectable-formulation tools. Background/§ 103.
• Opposition and prosecution record from EP 1 601 359 B1 — Opposition briefs (Dr. Reddy's (UK) Ltd., Martin Paul White, Tecnimede) and Helsinn responses/declarations (incl. the Bonadeo 37 C.F.R. § 1.132 declaration, Annexes 1–3, Mossi statement) — procedural; useful to trace what art opponents relied on, but not themselves prior art.

None of the non-patent references alone anticipates either claim (none discloses the full palonosetron/mannitol/EDTA/pH combination).

5. The reference that did invalidate the patent — the on-sale bar

Strictly, the "prior art" that defeated the asserted claim was not a printed reference at all:

• Helsinn's April 6, 2001 License Agreement and Supply & Purchase Agreement with MGI Pharma, Inc. (announced in a joint press release and in MGI's April 25, 2001 Form 8-K filed with the SEC). The Federal Circuit in Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017) held the asserted claims — including claim 2 of the '725 patent — invalid under the on-sale bar; the Supreme Court affirmed, holding a secret sale can trigger the bar, in Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 586 U.S. ___ (No. 17-1229, Jan. 22, 2019).
• Which claim: the record shows claim 2 of the '725 patent was asserted (PTAB materials: "the asserted claims … claim 2 of the '725 patent…"). Claim 1 was not asserted and was not part of that judgment; but because § 102(b)'s one-year bar applied to the same underlying 2001 offer, claim 1 rests on the same vulnerable factual footing.

6. Bottom line — ranked prior art

No cited patent or printed publication anticipates claim 1 or claim 2 of US 7,947,725 under § 102. The claims were instead invalidated (as to asserted claim 2) only by the § 102 on-sale bar arising from Helsinn's 2001 MGI agreements.

Caveats / limits

1. I could not query USPTO PatentCenter directly; the citation lists above are those mirrored on the patent's public record and should be verified against the file wrapper if certified data is needed.
2. Several non-patent citations (Won 1995, Eglen 1995, Tang 1998) were cross-checked against the Federal Circuit/PTAB briefing rather than the original journals; page-level verification of the journal articles was cut off by a step limit.
3. "Potentially anticipates" is used with the strict § 102 single-reference standard; where I say "§ 103 / background," the reference supplies an element or a motivation but not a complete anticipatory disclosure.
4. I did not auto-correct any patent number; each is reported as it appears in the sources (including the '725/'724/'424/'219/'094 family distinctions).

I'll ground this analysis in the prior-art references listed on the patent page, verifying key disclosures where I can.

Obviousness Analysis — U.S. Patent No. 7,947,725 (35 U.S.C. § 103)

Scope note. This section builds on the bibliography, plain-language claim read, and litigation history already generated. I do not repeat them. The prior art analyzed below is drawn from the references cited on the face of the '725 patent ("Citations (22)," "Non-Patent Citations (42)," and "Family Cites Families (16)"), as reproduced on the Google Patents page for US 7,947,725 B2 (https://patents.google.com/patent/US7947725/en). Where I supplement with the PTAB petition record or the sibling-patent disclosures, I flag it. No §103 ruling was ever reached on the merits of the '725 claims — the Federal Circuit and Supreme Court disposed of the asserted claim 2 on the on-sale bar (35 U.S.C. § 102), so the analysis below is an independent, hypothetical §103 assessment.

1. Legal framework applied

Under Graham v. John Deere, obviousness turns on (1) the scope and content of the prior art, (2) the differences between the prior art and the claims, (3) the level of ordinary skill, and (4) secondary considerations. Under KSR Int'l v. Teleflex, a formulation obvious to try, or a combination of known elements yielding predictable results, is obvious; and where a known problem exists, a "finite number of identified, predictable solutions" supports obviousness.

2. The claims to be tested

Both are composition claims over a sterile injectable aqueous palonosetron solution. Neither claim recites citrate buffer, a specific shelf-life, a method step, or a specific emesis indication beyond the functional preamble ("reducing emesis or reducing the likelihood of emesis"). That breadth matters: the claims are directed to a small set of conventional injectable excipients arranged at numerically recited concentrations and pH.

3. Level of ordinary skill in the art (POSITA)

A POSITA here is a formulation scientist with (i) an advanced degree (Ph.D./Pharm.D./M.S.) or equivalent experience in pharmaceutical formulation, (ii) several years developing sterile injectable aqueous products, and (iii) familiarity with the 5-HT₃-antagonist antiemetic class (ondansetron/Zofran®, granisetron/Kytril®, dolasetron/Anzemet®) and its commercial prescribing information. That skill level matters because pH optimization, tonicifier selection, and chelator addition at these concentrations were bench-level, routine formulation techniques — the very fact the patent's own specification relies upon.

4. The primary prior art

4.1 The "starting point" reference: Berger / U.S. Pat. No. 5,202,333 (Syntex, 1993) — cited on the '725 face

This is the palonosetron genus/utility patent. As the '725 specification itself quotes it, Example 13 of the '333 patent discloses an intravenous palonosetron formulation:

Thus the '333 patent expressly teaches a sterile (injectable-intended) aqueous palonosetron solution containing (a) palonosetron HCl, (b) an isotonicity agent (dextrose), and (c) a citrate system (citric acid + NaOH) — at pH 3.7. The '725 specification concedes this formulation "has a shelf stability of less than the 1–2 year time period required by health authorities," squarely framing the invention as the solution of an identified formulation problem, not the discovery of a new class.

Difference from claims: pH 3.7 (just outside 4–6); dextrose rather than mannitol; no EDTA. These three differences are each the subject of well-known formulation technique and other cited art.

4.2 The class-mate formulation references (all cited on the face of '725)

• U.S. Pat. No. 6,294,548 (Hoffmann-La Roche, 2001) — granisetron multidose vials. Its Example 1 ("Selection of a Buffer") states granisetron is stable over pH 2 to 7 and that citrate buffer was added to control the pH to a target of 6 (limits 5 to 7), specifically to stabilize pH during terminal autoclaving. This is closely analogous subject matter: a 5-HT₃ antagonist formulated as a buffered, terminally sterilized aqueous injection in the pH range overlapping 4–6.
• U.S. 2001/0020029 A1 (SmithKline Beecham) — companion multidose-vial disclosure for the same granisetron compound (also listed as a §102 reference on the '725 face under the name "New multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride").
• U.S. Pat. Nos. 4,886,808; 4,937,247; 5,034,398 (Beecham) and 4,695,578; 4,753,789; 4,929,632; 5,240,954; 5,344,658; 5,578,628; 5,578,632; 5,597,749; 5,622,720; 5,955,488; 6,063,802 (Glaxo) — the ondansetron and granisetron compound/formulation family, with the commercial Zofran® and Kytril® solutions buffered at acidic pH ranges (published labels teach pH ≈ 3–6 for these commercial IV solutions).
• U.S. Pat. Nos. 5,011,846 and 4,906,755 (Merrell Dow) — dolasetron (Anzemet®); the Anzemet® IV label identifies mannitol as the tonicifier (≈38.2 mg/mL), directly teaching mannitol in a setron IV product.

4.3 The "stability engineering" references from the Non-Patent Citations (all on the '725 face)

• Won, C.M. et al., "Photolytic and oxidative degradation of an antiemetic agent, RG 12915," Int. J. Pharm. 121 (1995) 95–105 — listed under the '725 "Non-Patent Citations." This is the single most probative obviousness reference. RG 12915 is a 5-HT₃ antiemetic bearing a quinuclidine (azabicyclo) tertiary amine, i.e., structurally and functionally analogous to palonosetron. Won teaches that:
  • the compound degrades by oxidation, including at the tertiary amine (N-oxide formation), which a POSITA would recognize as the same liability in palonosetron;
  • oxidation rate is proportional to substrate concentration — lower palonosetron concentration should degrade more slowly (supporting the low-concentration ranges of both claims);
  • degradation increases with acidity and is improved when pH is raised from strongly acidic toward mildly acidic — supporting pH 4–6 over the '333 patent's 3.7;
  • "EDTA is by far the most commonly used" chelating agent and "completely stabilized" the solution at 0.1% w/v (≈1 mg/mL) — squarely within the claimed 0.005–1.0 mg/mL EDTA.
• Lachman et al., The Theory and Practice of Industrial Pharmacy, 3d ed. (1986); Pharmaceutical Dosage Forms: Parenteral Medications, vol. 1, 2d ed. (1992); Modern Pharmaceutics, 2d ed. (1990) — standard texts teaching that injectables require (i) pH optimization for drug stability, (ii) tonicity adjustment with agents such as NaCl, dextrose, or mannitol, and (iii) optional chelating agents/stabilizers. These supply the "routine technique" element under KSR.
• Gatlin & Gatlin, "Formulation and administration techniques to minimize injection pain…," in Injectable Drug Development (1999) — teaches that injectable pH is selected with attention to tolerability/pain, i.e., a reason to move off pH 3.7 toward more physiological/mildly acidic ranges (overlapping 4–6).
• Barton, "Citrate Buffer Calculation" (2000) — routine buffer-design guidance.
• Avis, Pharmaceutical Dosage Form Design (cited in the related petition record; "Avis, Exh.1050, at 193–95, 207–08") — textbook support for buffers, chelators, and mannitol tonicification.

4.4 Additional "stabilized injectable" references in the Family Cites Family list

• DE 19833119 A1 (Roche Diagnostics, 2000) — "Storage-stable injectable solution … contains buffer, organic solvent, antioxidant and complexing agent" — teaches the general strategy of adding a chelating/complexing agent plus buffer to stabilize an injectable.
• US 6,132,758 (Schering, 2000) — "Stabilized antihistamine syrup"; CN 1525856 A — "Stable high-concentration injection"; JP S59-9539 B2 — nitroglycerin aqueous solution/complexation. Each supports the general proposition that aqueous drug stability is improved by pH/buffer/chelator control.
• US 5,272,137 (McNeil-PFC) — aqueous pharmaceutical compositions; US 6,287,592 (Boots) — aqueous buffered drink compositions.

Date caveat (flagging honestly): Not every item on the face is necessarily §102(b) prior art. In particular, WO 2003/100091 A1 (Epidauros) published 2003‑12‑04, and WO 2004/045615 A1 and WO 2004/073714 A1 (Helsinn) published in 2004 — after the Jan. 30, 2003 priority date — so they are not available as §102(b) art and are, at most, §102(a)/(e)-type references. The core references relied on below (Berger '333, '548, the Beecham/Glaxo/Merrell Dow setron patents, Won 1995, and the 1986–1999 textbooks) are all well before the critical date and are properly prior art.

5. Grounds of rejection

GROUND 1 — Berger '333 in view of Won 1995 and the standard formulation texts (primary ground; disposes of both claims)

Claim 1:

Claim 2 is the same solution at (i) the single value 0.05 mg/mL, (ii) pH 4.5–5.5, and (iii) mannitol 10–80 mg/mL. Each is a narrowing of Claim 1's own disclosed ranges, and each numerically recited value is either the commercial ALOXI® value or plainly within the routine optimization window. Under KSR, "a patent composed of several elements is not proved obvious merely by demonstrating that each of its elements was independently known"; but here the elements are not merely known individually — they are known to work together in the same class of product (buffered, tonicified, chelated 5‑HT₃-antagonist IV solutions; see Ground 2).

Why the POSITA would combine: all references are in the same field (5‑HT₃-antagonist injectable antiemetics) and address the same recognized problem — the poor shelf stability of the '333 pH‑3.7 formulation. The '333 patent supplies the drug and the starting formulation; Won 1995 supplies the mechanistic rationale (oxidative degradation of a quinuclidine antiemetic; concentration‑ and pH‑dependence; EDTA rescue); the textbooks and the setron labels supply the conventional toolbox (buffer to a mildly acidic pH, mannitol to tonicify, EDTA to chelate). The combination yields no more than the predictable sum of these known techniques.

GROUND 2 — Any commercial "setron" IV formulation (ondansetron / granisetron / dolasetron) in view of Berger '333 and Won 1995

Each commercial 5‑HT₃-antagonist IV solution cited on the '725 face already contains the same four functional components the claims require:

• ondansetron (Zofran®) — active + acid buffer (citrate/citric acid) + tonicifier (NaCl/dextrose) + stability aids;
• granisetron (Kytril®) — active + citrate/other buffer + tonicifier; and the '548 patent expressly buffers to pH 5–7 and autoclaves;
• dolasetron (Anzemet®) — active + mannitol as tonicifier (~38.2 mg/mL, within Claim 2's 10–80 mg/mL).

A POSITA formulating palonosetron, a later, more potent member of the identical drug class, would naturally turn to the then‑marketed setron injectables as templates and would use "the same components" — a buffered mildly acidic pH, a tonicifier (mannitol among the top choices), and a chelator (EDTA) as taught by Won. The PTAB petition record in this family captures exactly this reasoning: a declarant opined that "a person of ordinary skill in the art would have made a solution of palonosetron using the same components suggested by the prior art setron drug formulations" and "would have used an optimized pH (e.g., pH 5), included a suitable tonicifying agent (e.g., mannitol) and included an effective chelating agent (e.g., EDTA)… as a matter of common practice and particularly as suggested by the Won reference" (PTAB petition, https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1458462](/patent/1458462)/download-documents). That petition further states that claim 2 of the '725 patent was analyzed on these grounds and found obvious for the same reasons as the analogous claim 2 of the '724 patent. Note: the petition's §103 conclusion was not adjudicated — the claim was ultimately invalidated on the §102 on‑sale bar instead.

GROUND 3 — Berger '333 + '548 (granisetron buffer study) + Won 1995 (three-reference combination)

A tighter three-reference ground: '333 teaches the palonosetron IV solution; '548 teaches that buffering a setron injection to pH ~5–7 with citrate protects against pH drift during terminal sterilization (a stability rationale directly transferable to palonosetron); Won 1995 teaches EDTA + lowered concentration to arrest oxidative degradation. Combined, they render obvious a pH‑4–6, EDTA‑containing, low‑concentration palonosetron injection. The mannitol limitation comes from the dolasetron label and the textbook lists in Ground 1.

6. Reasonable expectation of success

High. Every recited element is a conventional, well‑characterized injectable excipient used at conventional concentrations (mannitol 10–80 mg/mL is the normal isotonicity window; EDTA 0.005–1.0 mg/mL spans the classical 0.01–0.1% chelator range). The references supply both the specific components and the mechanism (oxidation of a quinuclidine amine; pH‑ and concentration‑dependence), so a POSITA would expect a shelf‑stable product. The patent's own Examples 1–3 (pH 5 optimum; mannitol superior to NaCl; EDTA/citrate at 0.05%/20 mM) are presented as the results of standard design‑of‑experiment screening, which is itself evidence that the outcome was an optimization exercise rather than an unpredictable discovery.

7. Secondary considerations / expected rebuttal

Balanced conclusion on secondary considerations: absent quantification of a synergistic stability effect, the objective evidence is unlikely to overcome a strong prima facie case on these claims, especially given the KSR "finite number of predictable solutions" framing (optimize pH; pick a tonicifier from three candidates; add the standard chelator at its standard level). The most defensible non‑obviousness argument would be a quantified, synergistic mannitol/EDTA/pH‑5 stability effect — which the '725 specification does not supply as data.

8. Claim‑by‑claim §103 conclusion (as an independent hypothetical)

Overall: On this record, the '725 claims present a textbook KSR scenario — a known drug class, a known formulation problem (poor shelf stability of the '333 pH‑3.7 solution), and a small set of known, predictable solutions (buffering to mildly acidic pH, tonicifying with mannitol, chelating with EDTA, and lowering concentration). The claims are prima facie obvious under §103. That said, this conclusion was never tested at the Federal Circuit or Supreme Court for the '725 patent; both courts resolved the asserted claim (claim 2) on the on‑sale bar and did not reach obviousness. Anyone relying on this analysis should therefore treat it as a prosecution‑style §103 opinion, not as an adjudicated holding.

9. Caveats and limits (per operating rules)

1. I did not auto‑correct any patent or reference number; all identifiers (e.g., '333, '548, '724, '725, '424, '219, '094, '980) are reproduced as they appear in the sources.
2. The Won 1995 reference is listed under the '725 "Non‑Patent Citations"; its substantive content (EDTA 0.1%, concentration‑ and pH‑dependence) is drawn from quotations of that reference in the family's PTAB petition record, not from my independent reading of the original paper — treat the quoted specifics as reported, not verified against the journal text.
3. The PTAB petitions cited (PTAB petition IDs 1458461, 1458462, 1462972, 1459899) target sibling patents ('094, '219, '980, '724) and, per their own text, analyze claim 2 of the '725 patent; they are persuasive authority on the art mapping, not a ruling on the '725 claims. No IPR/PGR was filed directly against the '725 patent.
4. The §103 conclusion is my analytical opinion based on the face‑of‑patent art and the public record; it is not a legal conclusion and is not a substitute for an examiner's or court's determination.
5. Where a live source conflicted with the patent text, I deferred to the supplied authoritative patent text (per the full‑text source), and I flagged the one known date discrepancy (expiry) already noted in the prior section rather than resolving it here.